<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_SupBiotech-Paris_Bibliographie"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu"><UL><LI class="selected"><A href="/Team:SupBiotech-Paris/Bibliographie">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:SupBiotech-Paris/Bibliographie&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:SupBiotech-Paris/Bibliographie&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:SupBiotech-Paris/Bibliographie&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:SupBiotech-Paris/Bibliographie" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:SupBiotech-Paris/Bibliographie</H1><DIV id="bodyContent"><H3 id="siteSub">From 2009.igem.org</H3><DIV id="menuhaut"><TABLE style="background-color: transparent;" cellpadding="3" cellspacing="20" align="center"><TBODY><TR><TH align="center"><A href="/Team:SupBiotech-Paris/HomeFr#drapeau" title="Team:SupBiotech-Paris/HomeFr">Accueil</A></TH><TH align="center"><A href="/Team:SupBiotech-Paris/Equipe#drapeau" title="Team:SupBiotech-Paris/Equipe">Équipe</A></TH><TH align="center"><A href="/Team:SupBiotech-Paris/Gestion_de_projet#drapeau" title="Team:SupBiotech-Paris/Gestion de projet">Gestion de projet</A></TH><TH align="center"><A href="/Team:SupBiotech-Paris/MediaFr#drapeau" title="Team:SupBiotech-Paris/MediaFr">Galerie</A></TH><TH align="center"><A href="/Team:SupBiotech-Paris/Remerciement#drapeau" title="Team:SupBiotech-Paris/Remerciement">Remerciements</A></TH></TR></TBODY></TABLE></DIV><DIV id="menu" style="margin-top: 315px; background: transparent;"><DIV id="Partie" style="color: white; font-weight: bold; margin-bottom: -7px;">Projet</DIV><P><SPAN style="color: black;"><B>Introduction</B></SPAN><A href="/Team:SupBiotech-Paris/Th%C3%A9rapies_actuelles#drapeau" title="Team:SupBiotech-Paris/Thérapies actuelles">Thérapies actuelles</A><A href="/Team:SupBiotech-Paris/Th%C3%A9rapies_g%C3%A9niques#drapeau" title="Team:SupBiotech-Paris/Thérapies géniques">Thérapies géniques</A><SPAN style="color: black;"><B>Le DVS</B></SPAN><A href="/Team:SupBiotech-Paris/Introduction1Fr#drapeau" title="Team:SupBiotech-Paris/Introduction1Fr">Concept</A><A href="/Team:SupBiotech-Paris/Concept1Fr#drapeau" title="Team:SupBiotech-Paris/Concept1Fr">Vecteur Tissulaire</A><A href="/Team:SupBiotech-Paris/Concept2Fr#drapeau" title="Team:SupBiotech-Paris/Concept2Fr">Vecteur Cellulaire</A><A href="/Team:SupBiotech-Paris/Concept3Fr#drapeau" title="Team:SupBiotech-Paris/Concept3Fr">Plasmide thérapeutique</A><A href="/Team:SupBiotech-Paris/Conclusion1Fr#drapeau" title="Team:SupBiotech-Paris/Conclusion1Fr">Conclusion</A><SPAN style="color: black;"><B>Mise en application</B></SPAN><A href="/Team:SupBiotech-Paris/Ciblage_Tissulaire#drapeau" title="Team:SupBiotech-Paris/Ciblage Tissulaire">Ciblage Tissulaire</A><A href="/Team:SupBiotech-Paris/Ciblage_Cellulaire#drapeau" title="Team:SupBiotech-Paris/Ciblage Cellulaire">Action antitumorale</A><A href="/Team:SupBiotech-Paris/Modeling_du_traitement#drapeau" title="Team:SupBiotech-Paris/Modeling du traitement">Modeling du traitement</A><A href="/Team:SupBiotech-Paris/Conclusion3Fr#drapeau" title="Team:SupBiotech-Paris/Conclusion3Fr">Conclusion</A></P><DIV id="Partie" style="color: white; font-weight: bold; margin-bottom: -7px;">Ressources</DIV><P><A href="/Team:SupBiotech-Paris/BiobricksFr#drapeau" title="Team:SupBiotech-Paris/BiobricksFr">BioBricks</A><A href="/Team:SupBiotech-Paris/Mat%C3%A9riel_%26_M%C3%A9thode#drapeau" title="Team:SupBiotech-Paris/Matériel &amp; Méthode">Matériel &amp; Méthode</A><A href="/Team:SupBiotech-Paris/Bibliographie#drapeau" title="Team:SupBiotech-Paris/Bibliographie">Bibliographie</A></P><DIV id="Partie" style="color: white; font-weight: bold; margin-bottom: -7px;">Ethique &amp; sûreté</DIV><P><A href="/Team:SupBiotech-Paris/Biologie_Synthetique#drapeau" title="Team:SupBiotech-Paris/Biologie Synthetique">Éthique</A><A href="/Team:SupBiotech-Paris/S%C3%BBret%C3%A9#drapeau" title="Team:SupBiotech-Paris/Sûreté">Sûreté</A></P></DIV><TABLE id="toc" class="toc"><TBODY><TR><TD><DIV id="toctitle"><H2>Contents</H2></DIV><UL><LI class="toclevel-1 tocsection-1"><A href="#Th.C3.A9rapies"><SPAN class="tocnumber">1</SPAN><SPAN class="toctext">Thérapies</SPAN></A></LI><LI class="toclevel-1 tocsection-2"><A href="#Vectorisation"><SPAN class="tocnumber">2</SPAN><SPAN class="toctext">Vectorisation</SPAN></A></LI><LI class="toclevel-1 tocsection-3"><A href="#Vecteur_Tissulaire"><SPAN class="tocnumber">3</SPAN><SPAN class="toctext">Vecteur Tissulaire</SPAN></A></LI><LI class="toclevel-1 tocsection-4"><A href="#Vecteur_Cellulaire"><SPAN class="tocnumber">4</SPAN><SPAN class="toctext">Vecteur Cellulaire</SPAN></A></LI><LI class="toclevel-1 tocsection-5"><A href="#Plasmide_Th.C3.A9rapeutique"><SPAN class="tocnumber">5</SPAN><SPAN class="toctext">Plasmide Thérapeutique</SPAN></A></LI><LI class="toclevel-1 tocsection-6"><A href="#Action_antitumorale"><SPAN class="tocnumber">6</SPAN><SPAN class="toctext">Action antitumorale</SPAN></A></LI><LI class="toclevel-1 tocsection-7"><A href="#Ethique"><SPAN class="tocnumber">7</SPAN><SPAN class="toctext">Ethique</SPAN></A></LI><LI class="toclevel-1 tocsection-8"><A href="#S.C3.BBret.C3.A9"><SPAN class="tocnumber">8</SPAN><SPAN class="toctext">Sûreté</SPAN></A></LI></UL></TD></TR></TBODY></TABLE><H2><SPAN class="mw-headline" id="Th.C3.A9rapies"> Thérapies </SPAN></H2><TABLE><TBODY><TR style="background: grey; color:white; text-align: center; font-weight:bold;"><TD width="120px" height="40px">Chapitre
</TD><TD width="40px">Ref.
</TD><TD width="120px">Auteurs
</TD><TD width="560px">Titre
</TD><TD width="70px">Année
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Thérapie actuelle
</TD><TD>[1]
</TD><TD>Lechat P.
</TD><TD>Pharmacology
</TD><TD>2006
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Thérapie actuelle
</TD><TD>[2]
</TD><TD>Bruguerolle B.
</TD><TD>Biological rhythms and medications: a source of variability often neglected in pharmacology
</TD><TD>2008
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Thérapie genique
</TD><TD>[1]
</TD><TD>Kevin J. Scanlon and al.
</TD><TD>Cancer Gene Therapy: Challenges and Opportunities
</TD><TD>2004
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Thérapie genique
</TD><TD>[2]
</TD><TD>Gouze JN and al.
</TD><TD>A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer
</TD><TD>2003
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Thérapie génique
</TD><TD>[3]
</TD><TD>Centre for Genetics Education
</TD><TD><A href="http://www.genetics.com.au/index.asp" class="external free" rel="nofollow">http://www.genetics.com.au/index.asp</A></TD><TD>XXXX
</TD></TR></TBODY></TABLE><P><SPAN style="float: right"><A href="/Team:SupBiotech-Paris/Bibliographie#drapeau" title="Team:SupBiotech-Paris/Bibliographie">Haut de page</A></SPAN></P><H2><SPAN class="mw-headline" id="Vectorisation"> Vectorisation </SPAN></H2><TABLE><TBODY><TR style="background: grey; color:white; text-align: center; font-weight:bold;"><TD width="120px" height="40px">Chapitre
</TD><TD width="40px">Ref.
</TD><TD width="120px">Auteurs
</TD><TD width="560px">Titre
</TD><TD width="70px">Année
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[1]
</TD><TD>Couvreur P.
</TD><TD>L'encapsulation de médicament
</TD><TD>2003
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[2]
</TD><TD>Andrieux K. and al.
</TD><TD>Nanotechnology and new drug
</TD><TD>2003
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[3]
</TD><TD>Torchilin V.P.
</TD><TD>Recent Approaches to Intracellular Delivery of Drugs and DNA and Organelle Targeting
</TD><TD>2006
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[4]
</TD><TD>Davis M.E. and al.
</TD><TD>Nanoparticle therapeutics: an emerging treatment modality for cancer
</TD><TD>2008
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[5]
</TD><TD>Seow Y. and al.
</TD><TD>Biological Gene Delivery Vehicles: Beyond Viral Vectors
</TD><TD>2009
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[6]
</TD><TD>Decroly E.
</TD><TD>Vectorology
</TD><TD>2005
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[7]
</TD><TD>Robbins P.D. and al.
</TD><TD>Viral Vectors for Gene Therapy
</TD><TD>1998
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[8]
</TD><TD>Wei M.Q. and al.
</TD><TD>Bacterial targeted tumour therapy-dawn of a new era
</TD><TD>2008
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[9]
</TD><TD>Ryan R.M. and al.
</TD><TD>Use of bacteria in anti-cancer therapies
</TD><TD>2005
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[10]
</TD><TD>Mehnert
</TD><TD>Solid lipid nanoparticles: Production, characterization and applications
</TD><TD>2001
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[11]
</TD><TD>Lasic D.D.
</TD><TD>Liposomes in gene therapy
</TD><TD>1996
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[12]
</TD><TD>Lutten J. and al.
</TD><TD>Biodegradable polymers as non-viral carriers for plasmid DNA delivery
</TD><TD>2008
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[13]
</TD><TD>Jiskoot W. and al.
</TD><TD>Immunological Risk of Injectable Drug Delivery Systems
</TD><TD>2009
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[14]
</TD><TD>Head M. and al.
</TD><TD>Mechanism and computer simulation of immune complex formation, opsonization, and clearance
</TD><TD>1996
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[15]
</TD><TD>Koide H. and al.
</TD><TD>Particle size-dependent triggering of accelerated blood clearance phenomenon
</TD><TD>2008
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[16]
</TD><TD>Ishida T. and al.
</TD><TD>Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes
</TD><TD>2005
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[17]
</TD><TD>Wang XY and al.
</TD><TD>Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes
</TD><TD>2007
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[18]
</TD><TD>Tosi M.F. and al.
</TD><TD>Innate immune responses to infection
</TD><TD>2005
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vectorisation
</TD><TD>[19]
</TD><TD>Linkov I and al.
</TD><TD>Nanotoxicology and nanomedicine: making hard decisions
</TD><TD>2008
</TD></TR></TBODY></TABLE><P><SPAN style="float: right"><A href="/Team:SupBiotech-Paris/Bibliographie#drapeau" title="Team:SupBiotech-Paris/Bibliographie">Haut de page</A></SPAN></P><H2><SPAN class="mw-headline" id="Vecteur_Tissulaire"> Vecteur Tissulaire </SPAN></H2><TABLE><TBODY><TR style="background: grey; color:white; text-align: center; font-weight:bold;"><TD width="120px" height="40px">Chapitre
</TD><TD width="40px">Ref.
</TD><TD width="120px">Auteurs
</TD><TD width="560px">Titre
</TD><TD width="70px">Année
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vecteur Tissulaire
</TD><TD>[1]
</TD><TD>Ronald S. and al.
</TD><TD>Antimicrobial mechanisms of phagocytes and bacterial evasion strategies
</TD><TD>2009
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vecteur Tissulaire
</TD><TD>[2]
</TD><TD>Clark B. Inderlied and al.
</TD><TD>The Mycobacterium avium Complex
</TD><TD>1993
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vecteur Tissulaire
</TD><TD>[3]
</TD><TD>Nisheeth Agarwal and al.
</TD><TD>Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase
</TD><TD>2009
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vecteur Tissulaire
</TD><TD>[4]
</TD><TD>Hunter R.L. and al.
</TD><TD>Pathology of postprimary tuberculosis in humans and mice: contradiction of long-held beliefs
</TD><TD>2007
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vecteur Tissulaire
</TD><TD>[5]
</TD><TD>Axelrod S and al.
</TD><TD>Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide
</TD><TD>2008
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vecteur Tissulaire
</TD><TD>[6]
</TD><TD>Nicole N van der Wel and al.
</TD><TD>Subcellular localization of mycobacteria in tissues and detection of lipid antigens in organelles using cryo-techniques for light and electron microscopy
</TD><TD>2005
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vecteur Tissulaire
</TD><TD>[7]
</TD><TD>Claudia Nobrega and al.
</TD><TD>The thymus as a target for mycobacterial infections
</TD><TD>2007
</TD></TR></TBODY></TABLE><P><SPAN style="float: right"><A href="/Team:SupBiotech-Paris/Bibliographie#drapeau" title="Team:SupBiotech-Paris/Bibliographie">Haut de page</A></SPAN></P><H2><SPAN class="mw-headline" id="Vecteur_Cellulaire"> Vecteur Cellulaire </SPAN></H2><TABLE><TBODY><TR style="background: grey; color:white; text-align: center; font-weight:bold;"><TD width="120px" height="40px">Chapitre
</TD><TD width="40px">Ref.
</TD><TD width="120px">Auteurs
</TD><TD width="560px">Titre
</TD><TD width="70px">Année
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vecteur Cellulaire
</TD><TD>[1]
</TD><TD>Harrison Echols and al.
</TD><TD>Genetic Map of Bacteriophage Lambda
</TD><TD>1978
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vecteur Cellulaire
</TD><TD>[2]
</TD><TD>Joseph Sambrook and al.
</TD><TD>Molecular Cloning: A Laboratory Manual (Third Edition)
</TD><TD>2001
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vecteur Cellulaire
</TD><TD>[3]
</TD><TD>Court DL and al.
</TD><TD>A New Look at Bacteriophage lambda Genetic Networks
</TD><TD>2007
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vecteur Cellulaire
</TD><TD>[4]
</TD><TD>Ortega ME and al.
</TD><TD>Bacteriophage Lambda gpNu1 and Escherichia coli IHF Proteins Cooperatively Bind and Bend Viral DNA: Implications for the Assembly of a Genome-Packaging Motor
</TD><TD>2006
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vecteur Cellulaire
</TD><TD>[5]
</TD><TD>Feiss M. and al.
</TD><TD>Bactériophage Lambda Terminase and the Mechanism of Viral DNA Packaging
</TD><TD>2005
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vecteur Cellulaire
</TD><TD>[6]
</TD><TD>Hang JQ and al.
</TD><TD>The Functional Asymmetry of cosN, the Nicking Site for Bacteriophage λ DNA Packaging, Is Dependent on the Terminase Binding Site, cosB
</TD><TD>2001
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vecteur Cellulaire
</TD><TD>[7]
</TD><TD>Becker A and al.
</TD><TD>Bacteriophage lambda DNA : The begginning of the End
</TD><TD>1990
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Vecteur Cellulaire
</TD><TD>[8]
</TD><TD>Hochschild A and al.
</TD><TD>The bactériophage lambda cI protein finds an asymmetric solution
</TD><TD>2009
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Vecteur Cellulaire
</TD><TD>[9]
</TD><TD>Phoebe L.Stewart1 and al.
</TD><TD>Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization
</TD><TD>1997
</TD></TR></TBODY></TABLE><P><SPAN style="float: right"><A href="/Team:SupBiotech-Paris/Bibliographie#drapeau" title="Team:SupBiotech-Paris/Bibliographie">Haut de page</A></SPAN></P><H2><SPAN class="mw-headline" id="Plasmide_Th.C3.A9rapeutique"> Plasmide Thérapeutique </SPAN></H2><TABLE><TBODY><TR style="background: grey; color:white; text-align: center; font-weight:bold;"><TD width="120px" height="40px">Chapitre
</TD><TD width="40px">Ref.
</TD><TD width="120px">Auteurs
</TD><TD width="560px">Titre
</TD><TD width="70px">Année
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Plasmide thérapeutique
</TD><TD>[1]
</TD><TD>Ortega ME et al.
</TD><TD>Bacteriophage lambda gpNu1 and Escherichia coli IHF proteins cooperatively bind and bend viral DNA: implications for the assembly of a genome-packaging motor
</TD><TD>2006
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Plasmide thérapeutique
</TD><TD>[2]
</TD><TD>Joseph Sambrook and al.
</TD><TD>Molecular Cloning: A Laboratory Manual (Third Edition)
</TD><TD>2001
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Plasmide thérapeutique
</TD><TD>[3]
</TD><TD>Court DL and al.
</TD><TD>A New Look at Bacteriophage lambda Genetic Networks
</TD><TD>2007
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Plasmide thérapeutique
</TD><TD>[4]
</TD><TD>Feiss M. and al.
</TD><TD>Viral Genome Packaging Machines: Genetics, Structure and Mechanism
</TD><TD>2005
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Plasmide thérapeutique
</TD><TD>[5]
</TD><TD>Hang JQ and al.
</TD><TD>The Functional Asymmetry of cosN, the Nicking Site for Bacteriophage λ DNA Packaging, Is Dependent on the Terminase Binding Site, cosB
</TD><TD>2001
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Plasmide thérapeutique
</TD><TD>[6]
</TD><TD>Becker A and al.
</TD><TD>Bacteriophage lambda DNA : The begginning of the End
</TD><TD>1990
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Plasmide thérapeutique
</TD><TD>[7]
</TD><TD>Young et al.
</TD><TD>Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature
</TD><TD>2003
</TD></TR></TBODY></TABLE><P><SPAN style="float: right"><A href="/Team:SupBiotech-Paris/Bibliographie#drapeau" title="Team:SupBiotech-Paris/Bibliographie">Haut de page</A></SPAN></P><H2><SPAN class="mw-headline" id="Action_antitumorale"> Action antitumorale </SPAN></H2><TABLE><TBODY><TR style="background: grey; color:white; text-align: center; font-weight:bold;"><TD width="120px" height="40px">Chapitre
</TD><TD width="40px">Ref.
</TD><TD width="120px">Auteurs
</TD><TD width="560px">Titre
</TD><TD width="70px">Année
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Action antitumorale
</TD><TD>[1]
</TD><TD>Chunlin Yang et al
</TD><TD>Adenovirus-mediated Wild-Type p53 Expression Induces Apoptosis and Suppresses Tumorigenesis of Prostatic Tumor Cells
</TD><TD>1995
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Action antitumorale
</TD><TD>[2]
</TD><TD>Corrado Cirielli et al.
</TD><TD>Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma
</TD><TD>1999
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Action antitumorale
</TD><TD>[3]
</TD><TD>Su-Ping Ren et al.
</TD><TD>Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro
</TD><TD>2006
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Action antitumorale
</TD><TD>[4]
</TD><TD>Zhao-hua Qiu et al
</TD><TD>Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes
</TD><TD>2002
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Action antitumorale
</TD><TD>[5]
</TD><TD>Zhao-hua Qiu et al.
</TD><TD>Co-transfer of human wild-type p53 and granulocyte-macrophage colony-stimulating factor genes via recombinant adenovirus induces apoptosis and enhances immunogenicity in laryngeal cancer cells
</TD><TD>2001
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Action antitumorale
</TD><TD>[6]
</TD><TD>Markus Reiser et al.
</TD><TD>Induction of cell proliferation arrest and apoptosis in hepatoma cells through adenoviral-mediated transfer of p53 gene
</TD><TD>2000
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Action antitumorale
</TD><TD>[7]
</TD><TD>Louis L. Pisters et al.
</TD><TD>Evidence That Transfer of Functional p53 Protein Results in Increased Apoptosis in Prostate Cancer
</TD><TD>2004
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Action antitumorale
</TD><TD>[8]
</TD><TD>Susan C. Modesitt et al.
</TD><TD>In Vitro and in Vivo Adenovirus-mediated p53 and p16 Tumor Suppressor Therapy in Ovarian Cancer
</TD><TD>2001
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Action antitumorale
</TD><TD>[9]
</TD><TD>Yong-song GUAN et al.
</TD><TD>Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up
</TD><TD>2009
</TD></TR></TBODY></TABLE><P><SPAN style="float: right"><A href="/Team:SupBiotech-Paris/Bibliographie#drapeau" title="Team:SupBiotech-Paris/Bibliographie">Haut de page</A></SPAN></P><H2><SPAN class="mw-headline" id="Ethique"> Ethique </SPAN></H2><TABLE><TBODY><TR style="background: grey; color:white; text-align: center; font-weight:bold;"><TD width="120px" height="40px">Chapter
</TD><TD width="40px">Ref.
</TD><TD width="120px">Authors
</TD><TD width="560px">Title
</TD><TD width="70px">Year
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Ethique
</TD><TD>[1]
</TD><TD>Joël Rosnay
</TD><TD>Biologie de synthèse: Enjeux et défis pour l’humanité
</TD><TD>2004
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Ethique
</TD><TD>[2]
</TD><TD>Synbiosafe
</TD><TD><A href="http://www.synbiosafe.eu/forum/" class="external free" rel="nofollow">http://www.synbiosafe.eu/forum/</A></TD><TD>2008
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Ethique
</TD><TD>[3]
</TD><TD>Bernadette Bensaude Vincent, Dorothée Benoit-Browaeys
</TD><TD>Petite typologie de la biologie synthétique et enjeux éthiques
</TD><TD>2009
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Ethique
</TD><TD>[4]
</TD><TD>Anna Deplazes Æ Markus Huppenbauer
</TD><TD>Synthetic organisms and living machines
</TD><TD>2004
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Ethique
</TD><TD>[5]
</TD><TD>Schmidt M, Ganguli-Mitra A,and al.
</TD><TD>A priority paper for the societal and ethical aspects of synthetic biology
</TD><TD>2009
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Ethique
</TD><TD>[6]
</TD><TD>Parens E, Johnston J, Moses J.
</TD><TD>Ethics. Do we need &quot;synthetic bioethics&quot;?
</TD><TD>2009
</TD></TR></TBODY></TABLE><P><SPAN style="float: right"><A href="/Team:SupBiotech-Paris/Bibliography#drapeau" title="Team:SupBiotech-Paris/Bibliography">Back to top</A></SPAN></P><H2><SPAN class="mw-headline" id="S.C3.BBret.C3.A9"> Sûreté </SPAN></H2><TABLE><TBODY><TR style="background: grey; color:white; text-align: center; font-weight:bold;"><TD width="120px" height="40px">Chapitre
</TD><TD width="40px">Ref.
</TD><TD width="120px">Auteurs
</TD><TD width="560px">Titre
</TD><TD width="70px">Année
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Sûreté
</TD><TD>[1]
</TD><TD>Jonathan B. Tucker and al.
</TD><TD>The Promise and Perils of Synthetic Biology
</TD><TD>2006
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Sûreté
</TD><TD>[2]
</TD><TD>Synbiosafe
</TD><TD><A href="http://www.synbiosafe.eu/forum/" class="external free" rel="nofollow">http://www.synbiosafe.eu/forum/</A></TD><TD>2008
</TD></TR><TR style="background: white; text-align: center;"><TD height="40px">Sûreté
</TD><TD>[3]
</TD><TD>Vivagora
</TD><TD><A href="http://www.vivagora.org/IMG/pdf/CR-biosynth011009.pdf" class="external free" rel="nofollow">http://www.vivagora.org/IMG/pdf/CR-biosynth011009.pdf</A></TD><TD>2009
</TD></TR><TR style="background: #C0C0C0; text-align: center;"><TD height="40px">Sûreté
</TD><TD>[4]
</TD><TD>New Atlantis
</TD><TD><A href="http://www.thenewatlantis.com/publications/life-from-scratch" class="external free" rel="nofollow">http://www.thenewatlantis.com/publications/life-from-scratch</A></TD><TD>2004
</TD></TR></TBODY></TABLE><P><SPAN style="float: right"><A href="/Team:SupBiotech-Paris/Bibliographie#drapeau" title="Team:SupBiotech-Paris/Bibliographie">Haut de page</A></SPAN></P><DIV class="printfooter">
Retrieved from &quot;<A href="http://2009.igem.org/Team:SupBiotech-Paris/Bibliographie">http://2009.igem.org/Team:SupBiotech-Paris/Bibliographie</A>&quot;</DIV></DIV></DIV><DIV id="footer-box"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:SupBiotech-Paris/Bibliographie" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:SupBiotech-Paris/Bibliographie" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:SupBiotech-Paris/Bibliographie&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:SupBiotech-Paris/Bibliographie&amp;oldid=164363" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2009.igem.org:Privacy_policy" title="2009.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2009.igem.org:General_disclaimer" title="2009.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>